(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Help Your Business with Master Web based Promoting Arrangements - 2Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- 3Vote In favor of Your Favored Kind Of Organic product
- 4US FDA declines to approve Corcept's drug for rare hormonal disorder
- 5Independence from the rat race for Recent college grads: Systems and Tips
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- The Way to Monetary Freedom: A Viable Aide
- The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- Surveys of 6 Hot Savvy Beds
- Instructions to Boost Your True capacity with a Brain research Degree
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- Grasping Wrongdoings and Crimes: A Correlation
